GoAI
Get started
Korro Bio, Inc. logo

Korro Bio, Inc.

KRRO

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$13.18

+$0.22 · +1.70%

Aug 21, 4:00 PM ET

KRRO company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

52

Fair Value

Momentum

50

Neutral

Sentiment

49

Mixed

Risk resilience

22

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Industry
Biotechnology
Sector
Healthcare
Headquarters
US

Market position

Day range

Current $13.18

52-week range

Current $13.18

Open
$12.94
Previous close
$12.96
Volume
45.71K
Market cap
131.19M USD
50-day average
$12.5363
+5.13% above average
200-day average
$11.848
+11.24% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
96.92M USD
P/E (TTM)
-1.32×
P/B (TTM)
2.25×
P/S (TTM)
55.07×
EV / EBITDA
-1.17×
Earnings yield
-155.81%
Free cash flow yield
-105.08%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
72.75%
Operating margin
-3176.57%
Net margin
-4477.08%
Return on equity
-227.96%
Return on assets
-103.31%
Return on invested capital
-83.79%

Financial health

Debt / equity
0.41×
Current ratio
6.9×
Altman Z-score
-3.01
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends515%-1144%-2803%-4462%Gross margin, FY2024: 100.00%Gross margin, FY2025: 33.04%Operating margin, FY2024: -4047.12%Operating margin, FY2025: -1366.43%Net margin, FY2024: -3680.36%Net margin, FY2025: -1834.48%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2024 100.00%. Gross margin FY2025 33.04%. Operating margin FY2024 -4047.12%. Operating margin FY2025 -1366.43%. Net margin FY2024 -3680.36%. Net margin FY2025 -1834.48%.

Income trends

Revenue

6.39M USD+181.46%

Operating income

−87.34M USD+4.97%

Net income

−117.26M USD-40.30%
Income trends across reported periods18.76M USD−30.7M USD−80.16M USD−129.63M USDRevenue, FY2024: 2.27M USDRevenue, FY2025: 6.39M USDOperating income, FY2021: −35.49M USDOperating income, FY2022: −59M USDOperating income, FY2023: −84.53M USDOperating income, FY2024: −91.91M USDOperating income, FY2025: −87.34M USDNet income, FY2021: −21.96M USDNet income, FY2022: −58.03M USDNet income, FY2023: −81.17M USDNet income, FY2024: −83.58M USDNet income, FY2025: −117.26M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2024 2.27M USD. Revenue FY2025 6.39M USD. Operating income FY2021 −35.49M USD. Operating income FY2022 −59M USD. Operating income FY2023 −84.53M USD. Operating income FY2024 −91.91M USD. Operating income FY2025 −87.34M USD. Net income FY2021 −21.96M USD. Net income FY2022 −58.03M USD. Net income FY2023 −81.17M USD. Net income FY2024 −83.58M USD. Net income FY2025 −117.26M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue6.39M USD2.27M USD———
Cost of goods sold4.28M USD————
Gross profit2.11M USD2.27M USD———
Research and development65.58M USD63.64M USD57.25M USD42.2M USD23.81M USD
Selling, general, and administrative28.16M USD30.55M USD36.54M USD16.8M USD11.69M USD
Operating expenses89.45M USD94.18M USD84.53M USD59M USD35.49M USD
Interest income———947K USD—
Interest expense———118K USD—
Depreciation and amortization4.28M USD3.57M USD3.63M USD2.51M USD1.6M USD
Operating income−87.34M USD−91.91M USD−84.53M USD−59M USD−35.49M USD
Net income−117.26M USD−83.58M USD−81.17M USD−58.03M USD−21.96M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-12.48
FY2025
Latest fiscal-year revenue
6.39M USD
FY2025 · +181.46% year over year
Next fiscal-year EPS consensus
-5.31
FY2026 · 9 analysts
Next fiscal-year revenue consensus
300K USD
FY2026 · 6 analysts

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend19.3-70.42-160.13-249.85FY21FY22FY23FY24FY25FY26FY27FY28

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend7.03M4.47M1.92M-639.2KFY21FY22FY23FY24FY25FY26FY27FY28

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

12 ratings
Strong buy00%
Buy1083%
Hold217%
Sell00%
Strong sell00%

Recent analyst actions

12 institutions
Clear StreetupgradeHoldBuy

KRRO news

globenewswire.com

Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class…

Read source
zacks.com

All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy

Korro Bio, Inc. (KRRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read source
globenewswire.com

Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update

KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical trial in second half of 2026 Received Orphan Drug Designation from the European…

Read source
defenseworld.net

Reviewing Korro Bio (NASDAQ:KRRO) and Enlivex Therapeutics (NASDAQ:ENLV)

Enlivex Therapeutics (NASDAQ: ENLV - Get Free Report) and Korro Bio (NASDAQ: KRRO - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on…

Read source
globenewswire.com

Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class…

Read source
zacks.com

Korro Bio, Inc. (KRRO) Upgraded to Buy: What Does It Mean for the Stock?

Korro Bio, Inc. (KRRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read source

Corporate actions

Corporate action history

Stock split

Effective Nov 6, 2023

1:50

KRRO peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding KRRO

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
3.66M
Weight
0.00%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
2.44M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
1.06M
Weight
0.01%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
879.54K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
F/M Emerald Life Sciences Innovation ETF logoF/M Emerald Life Sciences Innovation ETFLFSC
Market value
859.52K
Weight
0.65%
AUM
74.65M USD
Expense ratio
0.54%
Price / 1D
$47.7953+0.83%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
758.65K
Weight
0.01%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
650.43K
Weight
0.00%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
505.95K
Weight
0.03%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research KRRO

research.disclaimer